Arix Bioscience PLC (LON:ARIX), the early-stage biotech investor, has updated on the progress of four of its portfolio companies following the ASCO and other events.
Imara Inc (NASDAQ: IMRA, 5.7% Arix holding) presented data from the Phase 2a clinical trial and its open-label extension (OLE) trial of IMR-687 in adults with sickle cell disease at the European Hematology Association (EHA) Annual Congress.
Results indicated that that IMR-687 has a well-tolerated safety profile as a monotherapy and in combination with hydroxyurea in both studies, with a lower annualised rate of vaso-occlusive crises. Arix has a 5.7% ownership stake in Imara.
Harpoon Therapeutics Inc (NASDAQ:HARP, 6.7% Arix holding) provided a pipeline update on its four clinical-stage programmes, noting that all demonstrate half-life extension, target engagement and T cell activation.
Harpoon also noted that three TriTAC clinical programmes (HPN424, HPN536 and HPN328) have shown tumour size reductions or stable disease, and meaningful treatment duration.
Autolus Inc (NASDAQ:AUTL, 0.8% Arix holding) announced a poster presentation related to AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) at the EHA Virtual Congress 2021.
LogicBio Inc (NASDAQ:LOGC, 9.3% Arix holding) meanwhile said the first patient has been dosed with LB-001, the company's investigational single-administration gene-editing therapy based on its proprietary GeneRide platform, in the SUNRISE Phase 1/2 clinical trial. Interim data from this trial is expected by the end of 2021.